Jean-Christophe Tellier, UCB CEO
May 13, 2022 07:38 AM EDT
R&D
FDA+

Quash­ing block­buster hopes, FDA spurns UCB’s IL-17 drug for plaque pso­ri­a­sis

Amber Tong

Af­ter a months-long wait, UCB has fi­nal­ly heard back from the FDA re­gard­ing its plaque pso­ri­a­sis drug. And the ver­dict is no.

The agency re­ject­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

Re­pare to lay off 75% of staff; Cas­tle Creek inks $75M roy­al­ty deal

Eli Lil­ly ex­pands Zep­bound sin­gle-dose vial op­tions at low­er price

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times